Vlado Perkovic
Overview
Explore the profile of Vlado Perkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
406
Citations
20782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Koshino A, Heerspink H, Jongs N, Badve S, Arnott C, Neal B, et al.
Nephrol Dial Transplant
. 2024 Sep;
PMID: 39304530
Background And Hypothesis: Studies in patients with heart failure have indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors increase iron use and enhance erythropoiesis. In this post-hoc analysis of the CREDENCE...
12.
Neuen B, Ostrominski J, Claggett B, Beldhuis I, Chatur S, McCausland F, et al.
J Am Coll Cardiol
. 2024 Sep;
84(22):2246-2250.
PMID: 39217558
No abstract available.
13.
Pratley R, Tuttle K, Rossing P, Rasmussen S, Perkovic V, Nielsen O, et al.
J Am Coll Cardiol
. 2024 Sep;
84(17):1615-1628.
PMID: 39217553
Background: People with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at high risk for heart failure (HF) and premature death from cardiovascular (CV) causes. The FLOW (Research...
14.
Mahaffey K, Tuttle K, Arici M, Baeres F, Bakris G, Charytan D, et al.
Eur Heart J
. 2024 Aug;
PMID: 39211948
Background And Aims: In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes mellitus (T2D) and chronic kidney...
15.
Neuen B, Fletcher R, Heath L, Perkovic A, Vaduganathan M, Badve S, et al.
Circulation
. 2024 Aug;
150(22):1781-1790.
PMID: 39210781
Background: GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in people with type 2 diabetes. We conducted a systematic review and...
16.
Ha J, Hiremath S, Jun M, Green S, Wheeler D, Coyne D, et al.
NEJM Evid
. 2024 Aug;
3(9):EVIDoa2300189.
PMID: 39186635
Background: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta-analysis, we assessed long-term safety of HIF...
17.
Kim D, Lv J, Hladunewich M, Jha V, Hooi L, Monaghan H, et al.
Kidney Int Rep
. 2024 Jul;
9(7):2168-2179.
PMID: 39081761
Introduction: The therapeutic effects of steroids in immunoglobulin A nephropathy (IgAN) global (TESTING) study reported that methylprednisolone reduces the risk of major kidney events in individuals with IgAN at high...
18.
Heerspink H, Perkovic V, Tuttle K, Pergola P, Mahaffey K, Patel U, et al.
J Am Soc Nephrol
. 2024 Jul;
35(12):1726-1736.
PMID: 39018154
No abstract available.
19.
Apperloo E, Neuen B, Fletcher R, Jongs N, Anker S, Bhatt D, et al.
Lancet Diabetes Endocrinol
. 2024 Jul;
12(8):545-557.
PMID: 38991584
Background: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are...
20.
Vaduganathan M, Cannon C, Jardine M, Heerspink H, Arnott C, Neuen B, et al.
Eur J Heart Fail
. 2024 Jun;
26(9):1967-1975.
PMID: 38932575
Aims: People with type 2 diabetes (T2D) face high risks of heart failure (HF) hospitalizations that are often recurrent, especially as kidney function declines. We examined the effects of canagliflozin...